Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer

Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Massimo Cristofanilli(Cornell University), Antonio Giordano(University of Siena), James M. Reuben(The University of Texas MD Anderson Cancer Center), Michal Mego(Comenius University Bratislava), Mario Giuliano(Regione Campania), Vicente Valero(The University of Texas MD Anderson Cancer Center), Emanuela Scarpi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Naoto T. Ueno(Breast Cancer Care), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center)
Clinical Breast Cancer
May 15, 2012
10.1016/j.clbc.2012.04.004
Cited by 126

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k